Varicella Zoster Infection Treatment Market is expected to reach a valuation of US$ 2.05 Billion by 2028, at a CAGR of 4.1%

The global Varicella Zoster Infection Treatment Market is predicted to be worth more than US$ 1.5 billion in 2020, with a CAGR of 4.1% expected to reach US$ 2.05 billion by 2028. According to Future Market Insights, acyclovir will account for more than 55.7% of the global varicella zoster infection treatment market in 2022.

Acute varicella may be complicated by secondary bacterial skin infections, cerebellitis, encephalitis, haemorrhagic complications, and viral and bacterial pneumonia. The climate is a core factor that seems to have an impact on the epidemiology of varicella. In most of the temperate climatic regions, 90% of the people are infected before adolescence. In tropical climates, VZV infection occurs later in life and adults are more susceptible to it than children.

On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorised by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population.

Get the Recently Updated Report of the Varicella Zoster Infection Treatment Market as a Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6466

Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications.

In order to cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships in order to make use of the technology of the other leading companies and are also focussing on research and development.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well.

These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Last few days to get reports at discounted prices, the offer expires soon!
Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-6466

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Key Players:

• Novartis AG,
• Pfizer Inc.,
• Abbott Laboratories,
• Sun Pharmaceuticals Industries Ltd.,
• Valeant Pharmaceuticals International Inc.,
• Teva Pharmaceutical Industries Ltd.,
• Dr. Reddy’s Laboratories, ltd.,
• Mylan N.V.  and
• GlaxoSmithKline

Varicella Zoster Infection Treatment – Market Segmentation – by Category

By Drug Type:

• Acyclovir
• Valacyclovir
• Famciclovir

Click here today to buy your full report @ https://www.futuremarketinsights.com/checkout/6466

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Hospital pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

About Future Market Insights (FMI) 

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs